bluebird bio Company Profile (NASDAQ:BLUE)

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLUE
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.2966 billion
  • Outstanding Shares: 40,950,000
Average Prices:
  • 50 Day Moving Avg: $103.56
  • 200 Day Moving Avg: $87.10
  • 52 Week Range: $37.05 - $123.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.60
  • P/E Growth: 0.23
Sales & Book Value:
  • Annual Revenue: $11.49 million
  • Price / Sales: 342.32
  • Book Value: $19.92 per share
  • Price / Book: 4.82
  • EBIDTA: ($250,640,000.00)
  • Net Margins: -2,402.03%
  • Return on Equity: -35.17%
  • Return on Assets: -27.25%
  • Current Ratio: 9.19%
  • Quick Ratio: 9.19%
  • Average Volume: 1.01 million shs.
  • Beta: 2.13
  • Short Ratio: 12.19
Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($1.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.76) by $0.08. The firm earned $6.83 million during the quarter, compared to analysts' expectations of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?

17 equities research analysts have issued 1 year price objectives for bluebird bio's shares. Their predictions range from $39.00 to $135.00. On average, they expect bluebird bio's share price to reach $98.82 in the next twelve months. View Analyst Ratings for bluebird bio.

What are analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
  • 2. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
  • 3. Cantor Fitzgerald analysts commented, "Updated Data." (6/5/2017)
  • 4. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board
  • Nick Leschly, President, Chief Executive Officer, Director
  • Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
  • Susanna Gatti High, Chief Operating Officer
  • Eric M. Sullivan, Principal Accounting Officer, Vice President - Finance, Treasurer
  • Philip D. Gregory Ph.D., Chief Scientific Officer
  • David M. Davidson M.D., Chief Medical Officer
  • Jason F. Cole Esq., Chief Legal Officer, Secretary
  • John O. Agwunobi M.D., Director
  • Douglas A. Melton, Director

Who owns bluebird bio stock?

bluebird bio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Taylor Wealth Management Partners (0.09%), Woodstock Corp (0.02%), Fox Run Management L.L.C. (0.02%), Aperio Group LLC (0.01%), Winslow Evans & Crocker Inc. (0.01%) and Bank of Montreal Can (0.00%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Taylor Wealth Management Partners. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Bank of Montreal Can and Aperio Group LLC. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $96.05.

MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  553 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $98.82 (2.88% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Morgan StanleyReiterated RatingEqual Weight$105.00 -> $103.00LowView Rating Details
7/6/2017Jefferies Group LLCReiterated RatingBuyLowView Rating Details
6/30/2017BTIG ResearchDowngradeBuy -> Neutral$37.05 -> $108.25MediumView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/24/2017Cantor FitzgeraldSet Price TargetSell$37.00 -> $39.00LowView Rating Details
6/23/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
6/23/2017WedbushReiterated RatingOutperform$121.00 -> $100.00LowView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
6/6/2017BMO Capital MarketsReiterated RatingBuy$108.00HighView Rating Details
6/5/2017Bank of America CorporationReiterated RatingHold$95.00HighView Rating Details
6/2/2017Maxim GroupUpgradeHold -> Buy$100.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016J P Morgan Chase & CoReiterated RatingBuy$120.00N/AView Rating Details
12/1/2016Leerink SwannBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
10/15/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$135.00N/AView Rating Details
10/14/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
5/5/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
11/5/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$162.00N/AView Rating Details
(Data available from 7/23/2015 forward)


Earnings History for bluebird bio (NASDAQ:BLUE)
Earnings by Quarter for bluebird bio (NASDAQ:BLUE)
Earnings History by Quarter for bluebird bio (NASDAQ BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($1.66)N/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for bluebird bio (NASDAQ:BLUE)
2017 EPS Consensus Estimate: ($7.23)
2018 EPS Consensus Estimate: ($6.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($1.88)($1.79)($1.83)
Q2 20175($1.89)($1.60)($1.75)
Q3 20175($1.94)($1.67)($1.79)
Q4 20175($2.03)($1.75)($1.86)
Q1 20181($1.78)($1.78)($1.78)
Q2 20181($1.68)($1.68)($1.68)
Q3 20181($1.71)($1.71)($1.71)
Q4 20181($1.74)($1.74)($1.74)
(Data provided by Zacks Investment Research)


Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)
Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.00View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.00View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.50View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.00View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.52View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.00View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.00View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.90View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.82View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.00View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.00View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.00View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.00View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.00View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.00View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.00View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.00View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.59View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.10View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.78View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.00View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.52View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.50View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.72View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.00View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.00View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.00View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.90View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.00View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
DateHeadline logoCommit To Buy bluebird bio At $50, Earn 10.4% Using Options - July 21 at 4:59 PM logoSanderson Farms, Inc. Names Suzanne Mestayer To Board Of Directors - July 20 at 6:11 PM logobluebird bio, Inc. (BLUE) Rating Lowered to Hold at Zacks Investment Research - July 18 at 7:58 PM logoETFs with exposure to bluebird bio, Inc. : July 14, 2017 - July 14 at 6:30 PM logoPioneering Cancer Gene Therapy by Novartis Backed by U.S. Panel - July 13 at 10:36 PM logoFDA Backs Pioneering Gene-Altering Cancer Treatment - HuffPost - July 13 at 5:35 PM logoInsider Selling: bluebird bio, Inc. (BLUE) Insider Sells 2,500 Shares of Stock - July 12 at 8:16 PM logoOpinion: Technical trading: These four stocks are breaking out of their pattern - MarketWatch - July 12 at 5:11 PM logoFDA panel backs Novartis' pioneering new cancer gene therapy - Reuters - July 12 at 5:11 PM logoSunTrust bullish on bluebird bio - Seeking Alpha - July 12 at 5:11 PM logoNovartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug - July 12 at 5:11 PM logobluebird bio, Inc. (NASDAQ:BLUE) Expected to Post Quarterly Sales of $5.70 Million - July 12 at 9:36 AM logoA Junior Freak Out - July 12 at 2:57 AM logobluebird bio, Inc. (BLUE) Insider Sells $120,588.00 in Stock - July 11 at 8:20 PM logobluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : July 11, 2017 - July 11 at 4:54 PM logoMorgan Stanley Reiterates Equal Weight Rating for bluebird bio, Inc. (BLUE) - July 10 at 9:40 PM logoPhilip D. Gregory Sells 2,250 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock - July 10 at 8:12 PM logo-$1.63 Earnings Per Share Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter - July 10 at 8:10 PM logoInsider Selling: bluebird bio, Inc. (BLUE) Insider Sells 5,000 Shares of Stock - July 7 at 8:16 PM logoJefferies Group LLC Reaffirms "Buy" Rating for bluebird bio, Inc. (NASDAQ:BLUE) - July 6 at 5:20 PM logobluebird bio, Inc. (BLUE) Raised to Buy at Zacks Investment Research - July 4 at 8:28 PM logobluebird bio, Inc. (BLUE) Receives "Buy" Rating from BTIG Research - July 2 at 1:20 PM logobluebird bio, Inc. (NASDAQ:BLUE) Downgraded by BidaskClub to "Buy" - July 1 at 8:04 AM logoMorning Movers: Tesla Gains on Musk Tweet; Bluebird Bio Falls - Barron's - June 30 at 4:41 PM logoBluebird Bio: Too Much Good News? - Barron's - June 30 at 4:41 PM logoBluebird Bio: Too Much Good News? - June 30 at 4:41 PM logoThe Cure For Cancer? Look At Your Blood - June 30 at 4:41 PM logoCan Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit? - June 30 at 4:40 PM logobluebird bio, Inc. (BLUE) Insider Sells $739,511.52 in Stock - June 30 at 4:36 PM logobluebird bio, Inc. (BLUE) Receives Consensus Recommendation of "Buy" from Analysts - June 30 at 9:54 AM logobluebird bio, Inc. to Post Q2 2017 Earnings of ($1.60) Per Share, Leerink Swann Forecasts (BLUE) - June 30 at 8:06 AM logoBTIG Research Lowers bluebird bio, Inc. (BLUE) to Neutral - June 30 at 7:54 AM logoNick Leschly Sells 25,000 Shares of bluebird bio, Inc. (BLUE) Stock - June 29 at 4:29 PM logobluebird bio Announces Pricing of Public Offering of Common Stock - June 28 at 4:41 PM logoBluebird Bio Gears Up for $350 Million Offering - 24/7 Wall St. - June 27 at 9:09 PM logoDaniel Lynch Sells 4,000 Shares of bluebird bio, Inc. (BLUE) Stock - June 27 at 7:51 PM logobluebird bio (BLUE) Reports Topline Interim Data from Starbeam Study of Lenti-D Drug Product in CALD - June 27 at 4:09 PM logobluebird bio (BLUE) Announces $350M Proposed Share Offering - - June 27 at 2:38 AM logobluebird bio (BLUE) Reports Topline Interim Data from Starbeam ... - - June 26 at 9:35 PM logoBRIEF-Bluebird bio reports updated clinical data from starbeam study - Reuters - June 26 at 9:35 PM logobluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D™ Drug Product in Cerebral Adrenoleukodystrophy (CALD) - June 26 at 4:33 PM logobluebird bio Announces Proposed Public Offering of Common Stock - June 26 at 4:33 PM logoAnalysts Offer Predictions for bluebird bio, Inc.'s FY2018 Earnings (BLUE) - June 26 at 10:42 AM logobluebird bio, Inc. (BLUE) Given a $39.00 Price Target at Cantor Fitzgerald - June 25 at 11:40 PM logoDrug Product at European Hematology Association (EHA) Annual Meeting - Business Wire (press release) - June 24 at 2:40 AM logobluebird bio, Inc. (BLUE) Upgraded to Strong-Buy by BidaskClub - June 23 at 11:28 PM logobluebird bio, Inc. (BLUE) Earns Buy Rating from Cowen and Company - June 23 at 5:18 PM logobluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at European Hematology Association (EHA) Annual Meeting - June 23 at 4:34 PM logobluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting - June 23 at 4:34 PM logobluebird bio's (BLUE) "Outperform" Rating Reiterated at Wedbush - June 23 at 4:32 PM



bluebird bio (BLUE) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff